DDXCELL丨吉满生物

🌟The global CGT market is projected to grow at a compound annual growth rate of over 36 percent from 2019-2025, to ~ €10 billion.  →Based on viral packaging, Genomeditech provides technical services and related products, such as reporter gene detection, virus packaging, engineered cell line construction, gene editing and drug screening and evaluation to meet the needs of drug discovery and development and to assist in the clinical filing of drugs. 👉learn more about our catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com hashtag#celllinedevelopment hashtag#cancertreatment hashtag#antibodies hashtag#drugdiscovery hashtag#CGT

#News 🎉ENHERTU Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer® ENHERTU (trastuzumab deruxtecan) is a HER2 directed ADC. HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors, including breast cancer. 👉learn more about our HER2 catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #HER2

#News ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer. Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial. CD-47 acts as a don't eat me signal to macrophages of the immune system which has made it a potential therapeutic target in some cancers. 👉learn more about our CD47 catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #CD47

#News Merck announced an agreement with Shanghai-based Curon Biopharmaceutical on last Friday, paying $700 million upfront to buy CN201, an investigational bispecific antibody for B cell-associated diseases. CN201 is an investigational bispecific T cell engager that targets both the CD3 and CD19 proteins. which is currently in clinical trials for haematological tumours. In addition, MSD plans to investigate the potential of CN201 as a novel scalable therapy for self-immune diseases. 👉learn more about our CD3/CD19 catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #celllinedevelopment #cancertreatment #drugdiscovery #antibody #Bispecificantibodies #CD3 #CD19

#News Novo has halted research and terminated the development of the candidate drug for the monthly GLP-1/GIP project, citing "portfolio considerations." The global market for GLP-1 meds currently stands at around $6 billion but is expected to balloon to some $100 billion by 2030. There are more than 100 GLP-1 agonist clinical trials currently underway, spanning more than 60 disease states. Genomeditech provides services for the construction of GLP-1R/GCGR/GIPR/FGF21 overexpression stable cell line/antibody service to meet the needs of drug discovery and development. 👉learn more about our catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #celllinedevelopment #cancertreatment #drugdiscovery #antibody #ADC #obesity #diabetes #cardioangiography #glp1

#News Genmab announced the decision by BioNTech to not participate in the further development of their collaborative akarizumab programme for reasons related to its portfolio strategy. Genmab regains rights to acasunlimab. BNT311/GEN1046 (acasunlimab) is a potential first-in-class bispecific antibody candidate combining PD-L1 checkpoint inhibition with 4-1BB costimulatory activation that is being developed for the treatment of solid tumors. 👉learn more about our catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #4-1BB #PD-L1 #bispecific antibody

#News 🎉Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody. #PD-L1 #VEGF IMM2510 is a novel, potentially best-in-class bispecific antibody consisting of an anti-PD-L1 antibody fused to a vascular endothelial growth factor (VEGF) receptor “trap” which binds VEGF. #CTLA-4 IMM27M is a next-generation anti-CTLA-4 antibody with enhanced ADCC activity, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies. 👉learn more about our catalog: https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #PD-L1 #VEGF #CTLA-4

#FcRn Argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update. Targeted FcRn drug Efgartigimod posts $478m in Q2 sales, up 78% year-on-year ! FcRn – shorthand for “neonatal Fc receptor” – is a protein and Fc receptor found in several types of tissues and cells in the body. FcRn blocking may help advance the treatment landscape for many autoimmune disorders. 👉learn more about our FcRn research products! https://lnkd.in/gvZBKb8e 📧 mkt.genomeditech@gmail.com #celllinedevelopment #cancertreatment #drugdiscovery #breakthrough #FcRn

#DLL3 Delta-like ligand 3 (DLL3) has emerged as an exciting target for precision cancer medicine. DLL3 is a protein expressed during fetal development that is involved in regulating cell differentiation. DLL3 is expressed on neuroendocrine cancers like small cell lung cancer but has restricted expression in normal tissue. Several investigation therapies that bind DLL3 are now in clinical development. These include antibody-drug conjugates (ADCs), bispecific antibodies - mainly T cell engagers, and T cell therapies. “More Than 15 Drugs Are In Pipeline With Majority Drugs For Small Cell Lung Cancer” 👉learn more about our DLL3 research products! https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com  #antibodydiscovery #antibodytherapeutics #celllinedevelopment #cancertreatment #antibodies #drugdiscovery #breakthrough #DLL3 Figure. The structure of DLL3 *The figure was derived from Frontiers in Immunology publication

#News 😟 A recent study found that HPV types in men found a prevalence rate of 12%. HPV (human papillomavirus) is a very common sexually transmitted infection that causes 4.5% of all cancers in women and men worldwide.In some European countries, the prevalence of high-risk HPV infection exceeds 15% in women. One study of oncogenic HPV types in men found a prevalence rate of 12%. The current ‘gold standard’ for measuring neutralizing anti-HPV antibodies is a manually performed pseudovirion-based neutralization assay (PBNA) using secreted alkaline phosphatase (SEAP) as reporter. 👉learn more about our HPV product Catalogs https://lnkd.in/gPyAytK2 📧 mkt.genomeditech@gmail.com #HPV #discovery #Pseudovirus Image source：Everyday Health